Company intelligence / Profile preview

Ivy Life Sciences

Taoyuan City, Taoyuan City, Taiwanivylifesciences.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Ivy Life Sciences has pioneered immune cell therapy development and clinical application since 2003, focusing primarily on cancer treatment. Their patented IKC® technology and CIK immune cell therapies have been used clinically with claims of improved survival and quality of life for patients. They operate licensed cell processing centers across Taiwan. No detailed published clinical trial results were found.

Therapeutic areas: Oncology
Modalities: Immune cell therapies (e.g., CIK cells, IKC® technology)
Industry: Biotech

Drug pipeline

1 asset

Immune Killer Cell

Partnerships

Partner medical centers throughout North, Central, and South Taiwan for clinical implementation of their therapies. No major international pharma partnerships disclosed.

Beyond the preview

Go deeper on Ivy Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ivy Life Sciences.